A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06) Meeting Abstract


Authors: Risi, E.; Biagioni, C.; Benelli, M.; Migliaccio, I.; McCartney, A.; Bonechi, M.; Guarducci, C.; Hilbers, F.; Di Cosimo, S.; Baselga, J.; Romagnoli, D.; Boccalini, G.; Vitale, S.; Grilli, A.; Bicciato, S.; Sotiriou, C.; Biganzoli, L.; Di Leo, A.; Malorni, L.
Abstract Title: A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06)
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 25s
Language: English
ACCESSION: WOS:000442916000077
DOI: 10.1200/JCO.2018.36.15_suppl.570
PROVIDER: wos
Notes: Meeting Abstract: 570 -- Source: Wos
Altmetric Score
MSK Authors
  1. Jose T Baselga
    410 Baselga